Nicolas Van de Velde
机构: Health Economics and Outcomes Research, Moderna Inc.
每年引用次数
引用次数
引用: 1,948
H-指数: 19
I10-指数 : 30
出版物: 102
HSD22 Vaccine Preparation Time, Cost, and Preference Comparison Between Pre-Filled Syringe Formulations and Vaccines That Require Reconstitution: A Targeted Literature Review
D Mehta , SM Kimball-Carroll , A Krivelyova , KZH Lai
Value in Health 26 ( 12) S298 -S298
2023
EPH124 Prediction Model to Evaluate the Impact of a Next Generation Bivalent Omicron-Containing COVID-19 Booster (MRNA. 1273.214) on Hospitalizations in Adults in Germany
A Müller , B Ultsch , A Nasir , T Certejan
Value in Health 25 ( 12) S215 -S215
2022
EE80 The Potential Clinical and Economic Benefits of a Next Generation Omicron-Containing (BA. 1) Bivalent Sars-Cov-2 Booster Compared to First Generation Prototype Boosters in Germany Assuming BA. 4/BA. 5 Dominance
M Maschio , B Schweikert , B Ultsch , R Cai
Value in Health 25 ( 12) S68 -S69
2022
EE174 Assessing the Cost-Effectiveness of an mRNA-Based Rsv Vaccine (mRNA-1345) Amongst Canadian Adults Aged≥ 60 Years
K Fust , M Kohli , P Ghaswalla , K Jayasundara
Value in Health 27 ( 6) S89 -S90
2024
EE594 Comparison of the Clinical and Economic Impact of Two COVID-19 Vaccines in Immunocompromised Patients in France
M Uhart , A Cheret , N Van de Velde , A Lee
Value in Health 26 ( 12) S167 -S167
2023
EE329 The Value-Based Price for a Bivalent COVID-19 Booster Vaccine in the United Kingdom
M Kohli , M Maschio , A Lee , S Carroll
Value in Health 26 ( 6) S119 -S120
2023
Indirect comparison of 96-week efficacy and safety of cabotegravir plus rilpivirine long-acting every 2 months versus dolutegravir/abaca-vir/lamivudine in suppressed HIV-1 infected participants
SJ Snedecor , MD Schroeder , J Scherzer , N Van de Velde
HIV MEDICINE 22 119 -119
2021
Medical needs for alternatives to daily oral HIV treatments in western Europe
L Clark , C Karki , J Noone , J Scherzer
HIV MEDICINE 21 29 -29
2020
Comparability of 48-week efficacy and safety of cabotegravir plus rilpivirine long-acting every 8 weeks to standard of care in patients with suppressed HIV-1
V Chounta , S Snedecor , N Van de Velde
HIV MEDICINE 21 28 -29
2020
Cost-utility analysis of long-acting cabotegravir plus rilpivirine for the treatment of HIV infection in the United Kingdom
B Parker , V Chounta , C Gait , O Hayward
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 23 37 -37
2020
Self-care and involvement in managed care among people living with HIV in Europe
C Okoli , G Corbelli , G Brough , N Van de Velde
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 23 39 -40
2020
Comparability of 48-week efficacy and safety of cabotegravir plus rilpivirine long-acting every 8 weeks to standard of care in suppressed HIV-1-infected patients
V Chounta , S Snedecor , S Wu , N Van de Velde
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 23 23 -24
2020
Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty
N. Van de Velde , M. Brisson , M.-C. Boily
American Journal of Epidemiology 165 ( 7) 762 -775
139
2007
PIN15 THE VALUE OF ACHIEVING OPTIMAL ADHERENCE WITH LONG-ACTING DIRECTLY OBSERVED ANTIRETROVIRAL THERAPY (LA DOT ART) AMONGST PATIENTS LIVING WITH HIV-1 INFECTION: A MODELLING STUDY
T. Ward , B. Parker , O. Hayward , I. Jacob
Value in Health 22
2019
PIN142 IMPACT OF ADHERENCE ON VIRAL SUPPRESSION AND DETERMINANTS OF ADHERENCE IN PATIENTS WITH HIV
V. Thakur , M. Joshi , D. Jha , V. Chounta
Value in Health 22
2019
Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11
M. Brisson , N. Van de Velde , M.-C. Boily
Sexually Transmitted Infections 87 ( 1) 41 -43
29
2011
Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity
Marc Brisson , Nicolas van de Velde , Eduardo L. Franco , Mélanie Drolet
The Journal of Infectious Diseases 204 ( 3) 372 -376
102
2011
Economic evaluation of human papillomavirus vaccination in developed countries.
Marc Brisson , Nicolas van de Velde , Marie-Claude Boily
Public Health Genomics 12 343 -351
96
2009
Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV
Louis S Matza , Timothy A Howell , Vasiliki Chounta , Nicolas van de Velde
Quality of Life Research 32 ( 2) 531 -541
1
2023
The health and economic burden of HPV infection, genital warts, cervical dysplasia and cervical cancer in Canada
M Brisson , N Van De Velde , MC Boily , P De Wals
Can J Infect Dis Med Microbiol 17 ( 6) 348 -349
10
2006